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ABSTRACT 
Objective: Reproductive and developmental toxicities of Eurycoma longifolia aqueous extract (PHYSTA®
Methods: Eurycoma longifolia aqueous extract at a dose of 250, 500 and 1000 mg/kg b. w. was administered daily by oral gavage during 14 day 
premating and 14 days mating period in both male and female, during gestation period and up to post natal day 3 in females. Animals were 
observed for clinical signs, morbidity, mortality, body weight development, food consumption and pub observation (number of live pups/litter, live 
birth index, implant sites, fetal resorption etc.). Male and females were sacrificed on day 29 and post natal day (PND) 4 respectively; then subjected 
to necropsy. 
) in male and female wistar rats were 
examined concerning its effect on male and female reproductive performance such as gonadal function, mating behavior, conception, development 
of the conceptus and parturition.  
Results: The result indicated non-significant predominant clinical signs, no mortality, and no toxicological relevance effect on body weight. In 
addition increased food consumption with no treatment related effect on litters, precoital interval and duration of gestation was observed. Pre and 
post natal data (Corpora lutea, implant sites, live pups, pre and post percent pre-implantation loss) remain unaffected. All pregnancies resulted in 
normal birth and delivery index remain unaffected. Survival of pups from PND 0 to PND 4 remained unaffected along with no treatment related 
gross external findings. No gross pathology findings and no statistically significant absolute and relative organ weight was observed. The 
histopathological evaluation does not revealed any lesions considered to be treatment related. 
Conclusion: In conclusion, the repeated dose administration of Eurycoma longifolia aqueous extract (PHYSTA®) to male Wistar rats for 28-29 days 
and female Wistar rats up to 54 days at dosages of 250, 500 and 1000 mg/kg b.w. revealed no major toxicological findings. As per the present 
investigation the non-observed-adverse event level (NOAEL) for Eurycoma longifolia aqueous extract (PHYSTA®
Keywords: Reproductive toxicity, Eurycoma longifolia; Developmental toxicity, PHYSTA. 
) is believed to be 1000 mg/kg body 
weight for reproductive and developmental toxicity.  
 
INTRODUCTION 
Historically, herbal medicine has been an important component of 
healthcare all over the world. With the advances in medical and 
biological sciences that resulted in the introduction of promising 
synthetic orthodox therapies for many conditions, the use of herbal 
medicine declined in the 20th century. Lately, however, there has 
been a resurgence of interest in the use of phytomedicinal products 
in the treatment of diseases [1, 2]. The World Health Organization 
(WHO) has documented the rapidly growing interest and economic 
importance of Traditional Medicine in health systems all over the 
world. 
Eurycoma longifolia (Jack) is a small tree that grows along the hilly 
slopes of the rainforests of Southeast Asia, including Indonesia, 
Malaysia, Thailand, Laos, Cambodia and Vietnam [3]. It has been used 
as a medicinal herb in Southeast Asia mainly to increase libido and to a 
lesser extent to improve general health [4]. Other traditional uses 
include treatment of malaria, bleeding, ulcers and hypertension [5].  
Eurycoma longifolia is reputed as an aphrodisiac and remedy for 
decreased male libido. Study showed Eurycoma longifolia aqueous 
extract demonstrated significant improvements in libido, sexual 
performance, satisfaction, and physical functioning with well 
tolerated daily dose of 300 mg in man [6]. Animal studies in mice 
have shown that LD50 of E. longifolia water was more than 3000 
mg/kg [7]. Acute, subacute and subchronic studies in rat have 
shown that 1000 mg/kg of E. longifolia water extract has no-
observed-adverse event and toxicity [8]. Although there have been a 
lot of E. longifolia preparations have been marketed and few safety 
and human studies have been conducted, there has not been study 
done on toxicity and safety of E. longifolia or E. longifolia–based 
products concerning reproductive and development. 
To expand our understanding of E. longifolia aqueous extract toxicity 
on reproductive outcomes and to evaluate further our interpolation 
of toxicities in humans systematically, specific life stages not covered 
by other types of toxicity studies were evaluated. The effects that 
may occur as a result of pre and postnatal chemical exposure were 
evaluated. Given the importance of E. longifolia aqueous extracts to 
reproductive outcomes, the possibility for systemic toxicity in 
pregnant and development, and the likelihood for effects on 
reproductive organs for males and females, we further evaluate 
these potential risks. Other parameters such as gonadal function are 
considered including the oestrous cycle, epididymal sperm 
maturation, mating behavior, conception, pregnancy, parturition, 
and lactation. The study was therefore designed to elucidate the 
possible effects of E. longifolia aqueous extract (PHYSTA®
MATERIALS AND METHODS 
) on male, 
female fertility and embryo fetal development in Wistar rats. The 
study was conducted to comply with OECD Principles of Good 
Laboratory Practice and OECD Guidelines for Testing of Chemicals, 
Section 4 No 421 “Reproductive/Development Toxicity Screening 
Test”. 
Preparation of extract 
The extract was obtained from a commercial batch of standardized 
E. longifolia aqueous extract (PHYSTA®) from Phytes Biotek Sdn 
Bhd, Malaysia. The standardized extract was prepared by a water 
extraction of E. longifolia roots using the patented high pressure 
water extraction technology (Patent no. US 7,132,117 B2), 
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comprising the steps of a) subjecting the dried root to hot water 
extraction by percolation; b) filtering; c) followed by concentration 
by condensation; d) freeze drying without any carrier such as 
maltodextrin or lactose; and e) size reduction obtaining the dry 
extract powder. The dry extract powder was standardized for 
content of (1)>22% of protein; (2)>35% of Glycosaponin and (3) 
0.8–1.5% Eurycomanone. 
Animals 
Young healthy male and nulliparous, non-pregnant female Wistar 
rats; 10 per treatment group, was purchased from Charles River, 
97633 Sulzfeld, Germany. They were acclimated for 5 days, weighed, 
given a unique identification number and were randomly assigned 
to one of the four different dosages (0, 250, 500, and 1000 mg/kg 
b.w. of E. longifolia extract) groups.  
They were housed in an automated climate control facility where the 
temperature was maintained at 22±3 °C, with a relative humidity of 
55±10% and 12/12 h light–dark cycle. The animal use and care 
guidelines established by the Art 9.2, No. 7 of the German Act on 
Animal Welfare were strictly followed. Rats were housed in IVC 
cages III II, polysulfone cages on altromin saw fibre bedding (Lot No: 
150610). 
Experimental design 
During the premating period 1 male and 1 female was housed per 
cage. After 14 days of administration of E. longifolia aqueous extract 
for both male and female, animals were paired (mating). During the 
mating period, 1 male and 1 female was matched from each 
treatment group and cohabited for a maximum of 14 days. The 
subsequent morning and the next morning there onwards the 
vaginal smear of female was checked to confirm the evidence of 
mating. Rats were separated after positive identification of a vaginal 
plug and/or sperm, after which a designation of gestational day [GD] 
0 was made. Females with unsuccessful mating were allowed to 
mate with other male of the same group. Females with no evidence 
of copulation up to 14 day mating period were sacrificed 26 days 
after the last day of the mating period.  
Males and females were sacrificed on day 29 and post natal day 
(PND) 4 respectively then subjected to necropsy. Randomly, body 
weights of males were taken weekly during entire study and at 
termination, whereas females were weighed weekly during pre 
mating period, on GD 0, GD 7, GD 14, GD 20 and on PND 0 (within 24 
hours of parturition) and PND 4 along with pups. Food consumption 
was measured weekly until the rats gave natural birth but not 
during the mating period. 
Dosing, feeding and animal care 
The test item was formulated in sterile water. The dose formulation 
was prepared on each day of administration by dissolving/ 
dispersing required amount of extract for each dose concentration in 
sterile water. The dose formulation was verified for the nominal 
concentration in study week 1 (first week of pre-mating period), 
week 3 (first week of mating), week 5 (gestation) and week 7 
(gestation/lactation) and checked for homogeneity in study week 1 
and 5 with coefficient of variation within 20%. Four groups 
comprised of 10 adults males and 10 non-pregnant nulliparous 
female Wistar rats were dose daily by oral gavage with 0, 250, 500 
and 1000 mg/kg b.w. per day of E. longifolia aqueous extract at dose 
volume of 10 ml/kg b.w. For each animal the individual dosing 
volume was calculated on the basis of the most recently measured 
body weight. Sterile water was used as vehicle and served as control 
group. Control animals were handled identically as treated groups. 
The highest doses of 1000 mg/kg b.w. were selected based on 
information of the highest dose from repeated dose toxicity studies. 
The item formulation was prepared freshly and administered daily 
during 14 days premating and 14 days mating period in both male 
and female, during the gestation period and up to post natal day 3 in 
females. Males were dosed for 28 days. Females were dosed 
throughout the study, 14 days of premating, mating, 14 days of 
gestation and 4 days lactation before sacrificed. Males were dosed 
daily for 28 days including 14 days of premating and then sacrificed. 
Additionally, all animals were fed an ad libitum supply of 
maintenance diet for rats Altromin 1324 and tap water, sulphur 
acidified to a pH of approximately 2.8. 
Clinical observations 
Animals were observed 1-2 times daily for general clinical signs. 
Litter observations 
Each litter was examined as soon as possible after delivery of the 
dam to establish the number and sex of pups, stillbirths, live births, 
runts and the presence of gross abnormalities. Live pups were 
counted, sexed and litters weighed within 24 hours of parturition, 
PND 0 and PND 4.  
Pathology, Histopathology and organ weights 
The sacrificed rats were examined macroscopically for any 
abnormalities and gross pathological changes. The numbers of 
implantation sites and corpora lutea were examined grossly in all 
pregnant females. The testes and epididymides of all males, and 
ovaries, uterus with the cervix of all females were weighed along 
with liver, kidneys, adrenals, thymus, spleen, brain, and heart. The 
following tissues from control and high dose group (1000 mg/kg 
b.w.) were examined for full histological evaluation: thymus, liver, 
kidney, adrenal, spleen, uterus with cervix, ovaries, vagina, testes, 
epididymides, accessory sex organs (prostate, seminal vesicles with 
coagulating glands) and all organs showing macroscopic lesions of 
all adult animals. All gross lesions were examined microscopically. 
These examinations were not extended to other dosage groups 
because no treatment related changes observed in the high dose 
group compared to control group. 
Dead pups and pups were killed at post-partum day 4 and were 
carefully examined for gross external abnormalities. 
Statistical analysis 
All data of each group were expressed as mean±SEM (n = 10). 
Statistical analyses were performed with ‘Graph Pad Prism (Version 
V)’ software and were carried out using one way ANOVA followed by 
Dunnet multiple comparison test to reveal any differences between 
control and test groups. Statistical significance was set at p<0.05. 
RESULTS AND DISCUSSION  
Mortality and clinical observation 
No mortality was observed during the entire period of the study. 
Predominant clinical signs were observed in the high and medium 
dose group. The animals were piloerection, aggressive behavior, 
moving the beddings, salivation and nasal discharge. 
Body weight 
In males, statistically significant decrease in body change was 
observed only between treatment day 28 and terminal sacrifice (day 
29) in the high dose group of 1000 mg/kg when compared to 
controls. As there was no effect on overall body weight change and 
due to lack of dose dependency and minimal differences of the body 
weight change, this effect on body weight change was considered to 
be unrelated to the E. longifolia aqueous extract. In females, although 
significant body weight change was observed in the high dose group 
of 1000 mg/kg during premating day 1-7, no significant body weight 
change was observed 7-14 days compared to control. During 
gestation period, statistically significant body weight changes were 
observed in the low dose group of 250 mg/kg b. w. However, due to 
lack of consistency and no dose dependency, no toxicological 
relevance could be attributed to the finding. 
Litter data 
Statistical analysis of litter weight data revealed no treatment 
related effect on group mean litter weight, total litter weight, male 
litter weight and female litter weight when compared with controls. 
No treatment related effect was observed on the total number of pup 
born, number of males, number of females, sex ratio, live pups, still 
birth and runt. No treatment related gross external findings were 
observed in pups from any of the treated group during the lactation 
period. 
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Table 1: Body weight change (g)–males 
  Group (n = 10 each group)   
 Day of treatment 0 mg/kg 250 mg/kg 500 mg/kg 1000 mg/kg 
Pre mating  1-7 12.70±6.45 17.20±5.88 13.10±4.33 11.60±8.04 
  7-14 22.60±6.00 22.90±7.82 15.20±7.58 18.20±7.63 
Mating/Post Mating  14-21 6.50±3.54 7.70±5.36 5.50±5.80 10.10±4.93 
  21-28 7.40±4.25 10.40±4.01 10.40±5.02 11.50±6.31 
  28-29 3.60±2.41 1.30±3.09 1.50±3.37 -0.30*±2.95 
  1-29 52.80±16.67 60.26±14.20 45.70±15.43 51.10±18.84 
*significant (p<0.05) as determined with the individual data 
 
 
Fig. 1: Body weight of males supplemented with E. longifolia 
aqueous extract for the entire period of the study 
 
Fig. 2: Body weight of females supplemented with E. longifolia 
aqueous extract for the entire period of the study 
 
Table 2: Body weight change (g)–females 
  Group (n = 10 each group)   
Day of treatment 0 mg/kg 250 mg/kg 500 mg/kg 1000 mg/kg 
Pre mating 1-7 7.10±2.81 7.30±4.30 4.90±2.42 1.70*±3.74 
 7-14 4.80±2.35 8.20±3.39 6.00±5.75 8.60±6.79 
Gestation 0-7 14.70±3.50 20.00*±2.93 13.50±3.37 12.63±5.07 
 7-14 27.40±5.87 19.25*±11.29 26.80±3.79 24.25±3.06 
 14-20 59.20±10.45 50.25±22.10 54.10±7.56 48.63±8.50 
 0-20 101.30±13.89 89.50±33.20 94.40±11.74 85.50±12.35 
Lactation 0-4 11.70±10.53 6.38±7.87 -2.80±9.67 -2.13±8.79 
*significant (p<0.05) as determined with the individual data 
 
Table 3: Precoital Interval and duration of gestation (days) 
Parameter 0 mg/kg 250 mg/kg 500 mg/kg 1000 mg/kg 
Precoital Interval 5.50±5.083 1.78*±0.972 2.20*±1.229 2.10*±1.449 
 n = 9 n = 9 n = 10 n = 10 
Duration of Gestation 21.60±0.516 21.50±0.535 21.60±0.516 21.75±0.463 
 n = 10 n = 8 n = 10 n = 8 
*significant (p<0.05) as determined with the individual data 
[ 
Table 4: Reproductive performance of pairs during a 21-day breeding phase of rats exposed to E. longifolia aqueous extract 









Dams at term 10 8 10 8 
Precoital interval 5.50±5.083 1.78*±0.972 2.20*±1.229 2.10*±1.449 
Duration of Gestation 21.60±0.516 21.50±0.535 21.60±0.516 21.75±0.463 
Corpora lutea 14.00±1.76 14.75±2.43 14.70±2.41 14.00±4.34 
Implantation sites 12.60±1.58 12.25±2.76 12.00±2.75 12.63±1.85 
Pups per litter 12.30±1.42 10.38±4.81 11.10±2.38 11.88±2.17 
Live pups per litter on PND0 12.20±1.40 10.38±4.81 11.00±2.31 11.00±3.21 
Live pups per litter on PND4 12.20±1.40 10.25±5.09 10.80±2.35 10.75±2.82 
% Pre implantation loss 9.15±11.93 16.71±15314 16.43±22.15 6.79±11.90 
% Pre implantation loss 2.20±3.54 15.75±31.29 6.77±13.34 10.55±19.36 
% Mortality/cannibalism (PND1-4) 0.77±2.43 12.50±35.36 2.10±4.77 4.74±9.35 
Viability index 9 (%) 99.23±2.43 87.50±35.36 97.90±4.77 95.94±7.78 
Copulation index (%) 100 90 100 100 
Fertility index (%) 100 80 100 80 
Delivery index (%) 100 100 100 100 
Data represent mean±SD and were analyzed by one way ANOVA followed by Dunnett’s multiple comparison test, to identify differences between 
treatments, aStarting number of breeding pairs, * Significant (p<0.05) E. longifoloia aqueous extract differences, between treatment groups and 
controls. One male and one female from each treatment group were cohabited for 14–21 days and then separated. 
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Reproductive performance  
No treatment related effect was observed on the duration of 
gestation when compared with controls.  
Statistically significant decrease in precoital interval was observed 
in all treated groups when compared with controls showing positive 
effects that could be attributed to E. longifolia aqueous extract. 
Pathology  
Gross pathological observation of males, females at scheduled 
necropsy revealed no treatment related findings. 
The histopathological evaluation of males and females reproductive 
organs did not reveal any histopathological lesions considered to be 
to E. longifolia aqueous extract related. 
 
 
Fig. 3: Absolute organs weight of females supplemented with E. 
longifolia aqueous extract for the entire period of the study 
 
Fig. 4: Absolute organs weight of males supplemented with E. 
longifolia aqueous extract for the entire period of the study 
 
Table 5: Absolute organs weight of females supplemented with E. longifolia aqueous extract for the entire period of the study 









Liver 9.97±0.91 9.98±1.45 10.03±0.98  9.75±1.18 
Brain 1.84±0.06 1.82±0.09 1.82±0.08 1.82±0.08 
Heart 0.79±0.08 0.77±0.10 0.79±0.10  0.78±0.05 
Spleen 0.67±0.15 0.57±0.05 0.56±0.07  0.67±0.07 
Kidney (Left) 0.79±0.05 0.82±0.03 0.78±0.08  0.78±0.06 
Kidney (Right) 0.82±0.08 0.84±0.05 0.84±0.08  0.83±0.07 
Adrenal (Left) 0.03±0.005 0.03±0.003 0.03±0.003  0.03*±0.004 
Adrenal (Right) 0.03±0.006 0.03±0.004 0.03±0.004  0.03*±0.002 
Ovary (Left) 0.05±0.006 0.04±0.009 0.05±0.009  0.04±0.01 
 Ovary (Right) 0.04±0.009 0.04±0.005 0.04±0.006  0.04±0.006 
Uterus with Cervix 0.74±0.11 0.75±0.08 0.68±0.11  0.67±0.09 
Thymus 0.16±0.03 0.21±0.04 0.17±0.03 0.17±0.04 
Data represent mean±SD and were analyzed by one way ANOVA followed by Dunnett’s multiple comparison test, as determined with individual 
data, a
 
The number of females per treatment group,* Significant (p<0.05) E. longifolia aqueous extract as determined with the individual data 
Table 6: Absolute organs weight of males supplemented with E. longifolia aqueous extract for the entire period of the study 









Liver 11.66±1.12 11.77±0.90 11.19±1.18 11.90±1.46 
Brain 2.01±0.12 1.99±0.17 1.98±0.08 1.97±0.12 
Heart 1.12±0.09 1.13±0.08 1.05±0.09 1.11±0.07 
Spleen 0.70±0.08 0.79±0.08 0.75±0.11 0.74±0.15 
Kidney (Left) 1.31±0.11 1.40±0.09 1.31±0.12 1.36±0.07 
Kidney (Right) 1.36±0.11 1.42±0.10 1.33±0.12 1.38±0.14 
Adrenal (Left) 0.03±0.004 0.03±0.004 0.03±0.002 0.03±0.004 
Adrenal (Right) 0.03±0.008 0.03±0.003 0.02±0.003 0.03±0.003 
Testes (Left) 1.73±0.12 1.74±0.13 1.77±0.12 1.74±0.12 
 Testes (Right) 1.73±0.14 1.72±0.08 1.75±0.10 1.72±0.14 
Epididymides (Left) 0.62±0.05 0.67±0.05 0.62±0.34 0.64±0.05 
Epididymides (Right) 0.59±0.04 0.65*±0.04 0.61±0.03 0.61±0.03 
Thymus 0.36±0.08 0.39±0.04 0.34±0.05 0.38±0.08 
Data represent mean±SD and were analyzed by one way ANOVA followed by Dunnett’s multiple comparison test, as determined with individual 
data, aThe number of males per treatment group, * Significant (p<0.05) E. longifolia aqueous extract as determined with the individual data 
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Table 7: Organ weight ratios of males supplemented with E. longifolia aqueous extract for the entire period of the study 









Terminal body weight 368.10±22.87  374.60±19.13  361.30±15.67 367.60±25.27  
Organ to body weight ratios     
Liver 3.16±0.19 3.14±0.18 3.09±0.20 3.23±0.22 
Brain 0.55±0.04 0.53±0.04 0.54±0.02 0.53±0.04 
Heart 0.30±0.02 0.30±0.01 0.29±0.02 0.30±0.01 
Spleen 0.19±0.01 0.21±0.02 0.20±0.02 0.20±0.03 
Kidney (Left) 0.35±0.02 0.37±0.02 0.36±0.02 0.37±0.02 
Kidney (Right) 0.37±0.03 0.38±0.02 0.36±0.02 0.37±0.03 
Adrenal (Left) 0.008±0.001 0.008±0.001 0.008±0.001 0.008±0.001 
Adrenal (Right) 0.009±0.001 0.008±0.001 0.007±0.000 0.008±0.000 
Testes (Left) 0.47±0.03 0.46±0.02 0.45±0.10 0.47±0.05 
 Testes (Right) 0.47±0.04 0.46±0.02 0.45±0.10 0.47±0.05 
Epididymides (Left) 0.17±0.01 0.18±0.01 0.17±0.01 0.17±0.02 
Epididymides (Right) 0.16±0.01 0.17±0.01 0.17±0.01 0.16±0.01 
Thymus 0.09±0.02 0.10±0.01 0.09±0.01 0.10±0.02 
Data represent mean±SD and were analyzed by one way ANOVA followed by Dunnett’s multiple comparison test, to identify differences between 
treatments, a
 
The number of males per treatment group. 
Table 8: Organ weight ratios of females supplemented with E. longifolia aqueous extract for the entire period of the study 









Terminal body weight 250.50±16.54  246.63±16.61  245.30±15.64 235.13±16.53  
Organ to body weight ratios     
Liver 3.98±0.30 3.88±0.49 4.09±0.35 4.14±0.38 
Brain 0.73±0.05 0.71±0.11 0.74±0.05 0.77±0.05 
Heart 0.31±0.01 0.30±0.04 0.32±0.04 0.33±0.02 
Spleen 0.26±0.05 0.22±0.04 0.23±0.03 0.28±0.03 
Kidney (Left) 0.31±0.02 0.32±0.04 0.32±0.02 0.33±0.03 
Kidney (Right) 0.33±0.03 0.33±0.05 0.34±0.04 0.35±0.02 
Adrenal (Left) 0.01±0.002 0.01±0.002 0.01±0.001 0.01±0.002 
Adrenal (Right) 0.01±0.002 0.01±0.002 0.01±0.001 0.01±0.001 
Ovary (Left) 0.02±0.002 0.02±0.003 0.02±0.004 0.02±0.005 
 Ovary (Right) 0.02±0.003 0.02±0.003 0.02±0.002 0.02±0.002 
Uterus with Cervix 0.29±0.03 0.30±0.06 0.28±0.06 0.29±0.05 
Thymus 0.06±0.01 0.08±0.10 0.06±0.01 0.07±0.01 




The study has shown that standardized E. longifolia aqueous extract 
(PHYSTA
 The number of females per treatment group. 
®
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